Molecular targets for radiation oncology in prostate cancer
Department of Radiation Oncology, Department of Cell Biology, Department of Surgery
Neoplasms | Oncology | Therapeutics
Recent selected developments of the molecular science of prostate cancer (PrCa) biology and radiation oncology are reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combination with RT for patient care. We provide a synopsis of the information to date regarding molecular biology of PrCa, and potential integrated research strategy for improved treatment of PrCa. Many patients with early-stage disease at presentation can be treated effectively with androgen ablation treatment, surgery, or RT. However, a significant portion of men are diagnosed with advanced stage/high-risk disease and these patients progress despite curative therapeutic intervention. Unfortunately, management options for these patients are limited and are not always successful including treatment for hormone refractory disease. In this review, we focus on molecules of extracellular matrix component, apoptosis, androgen receptor, RUNX, and DNA methylation. Expanding our knowledge of the molecular biology of PrCa will permit the development of novel treatment strategies integrated with RT to improve patient outcome.
Rights and Permissions
Citation: Front Oncol. 2011 Jul 13;1:17. doi: 10.3389/fonc.2011.00017. eCollection 2011. Link to article on publisher's site
Wang, Tao; Languino, Lucia R.; Lian, Jane; Stein, Gary; Blute, Michael; and Fitzgerald, Thomas J., "Molecular targets for radiation oncology in prostate cancer" (2011). Radiation Oncology Publications and Presentations. Paper 49.